Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country

References

• Stephens D, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-210; PMID:17604802; http://dx.doi.org/10.1016/S0140-6736(07)61016-2
   PubMed Web of Science ®Google Scholar
• Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines 2010; 9(3): 285-98; PMID:20218857; http://dx.doi.org/10.1586/erv.10.3
   PubMed Web of Science ®Google Scholar
• Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27(Suppl 2):B51-63; PMID:19477562; http://dx.doi.org/10.1016/j.vaccine.2009.04.063
   PubMed Web of Science ®Google Scholar
• Halperin S, Bettinger J, Greenwood B, Harrison L, Jelfs J, Ladhani S, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30:B26-36; PMID:22178525; http://dx.doi.org/10.1016/j.vaccine.2011.12.032
   PubMedGoogle Scholar
• Pan American Health Organization. Informe Regional de SIREVA II: Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores, 2010.OPS. Documentos técnicos, Tecnologías Esenciales de Salud 2009. Washington, DC 2011: Pan American Health Organization, Available at: http://new.paho.org/hq/index.php?option=com_content&task=blogcategory&id=3609&itemid=3953;2011. Accessed 12.10.2012.
   Google Scholar
• Alerta Epidemiológica Meningitis meningocócica(Fiebre cerebroespinal) 24 de abril 2012 http://new.paho.org/hq/index.php?option=com_docman&task=doc_view&gid=17445&Itemid=/ acceded 10.04.2012.
   Google Scholar
• López E, Debbag R. Meningococcal disease: always present. Serogroup changes in the Southern Cone. Rev Chilena Infectol 2012; 29(6):587-94; PMID:23412025; http://dx.doi.org/10.4067/S0716-10182012000700001
   PubMedGoogle Scholar
• Safadi MAP, Cintra OAL. Epidemiology of meningococcal disease in Latin America: current situation and opportunities for prevention. Neurological Research 2010; 32: 263-71; PMID:20406604; http://dx.doi.org/10.1179/016164110X12644252260754
   PubMed Web of Science ®Google Scholar
• Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infectious Disease 2009; 9(7):418-27; PMID:19555901; http://dx.doi.org/10.1016/S1473-3099(09)70132-X
   PubMed Web of Science ®Google Scholar
• Finne J, Bitter-Suermann D, Goridis C, Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987; 138:4402-07; PMID:3108388
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomized trials. Lancet 2013; 381(9869):825-35; PMID:23324563; http://dx.doi.org/10.1016/S0140-6736(12)61961-8
   PubMed Web of Science ®Google Scholar
• Santolaya ME, O'Ryan ML, Valenzuela MT, Prado V, Vergara R, Muñoz A, Toneatto D, Graña G, Wang H, Clemens R, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile. Lancet 2012; 379:617-24; PMID:22260988; http://dx.doi.org/10.1016/S0140-6736(11)61713-3
   PubMed Web of Science ®Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol 2011; 18(3):483-86; PMID:21177912; http://dx.doi.org/10.1128/CVI.00304-10
   PubMed Web of Science ®Google Scholar
• Sadarangani M, Pollard A. Serogroup B meningococcal vaccines – an unfinished story. Lancet Infect Dis 2010; 10:112-24; PMID:20113980; http://dx.doi.org/10.1016/S1473-3099(09)70324-X
   PubMed Web of Science ®Google Scholar
• Snape M, Dawson T, Oster P, Evans A, John T, Ohene-Kena B, Findlow J, Yu LM, Borrow R, Ypma E, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life. a randomized comparative trial. Pediatr Infect Dis J 2010; 29:e71-9; PMID:20844462; http://dx.doi.org/10.1097/INF.0b013e3181faa6be
   PubMedGoogle Scholar
• Pollard A. Global epidemiology of meningococcal disease and vaccine efficacy. Pediatr Infect Dis J 2004; 23(12 Suppl):S274-79; PMID:15597069
   PubMedGoogle Scholar
• Tappero J, Vega J. Estudio colaborativo para el estudio de secuelas de enfermedad meningocócica grupo b. Santiago de Chile 1993. Preliminary results, unpublished.
   Google Scholar
• Castillo L, Maldonado A, García J, Silva W, Ulloa MT, Valenzuela MT, Bustos R, Valenzuela ME, Gassibe MP. Characterization of Neisseria meningitidis isolated from systemic infections. Chile, 1992-1993. Rev Med Chil 1994; 122(7):760-7; PMID:7732225
   PubMed Web of Science ®Google Scholar
• Cruz C, Pavez G, Aguilar E, Grawe L, Cam J, Mendez F, Garcia J, Ruiz S, Vicent P, Canepa I, et al. Serotype-specific outbreak of group B meningococcal disease in Iquique, Chile. Epidemiology and Infection 1990; 105:119-26; PMID:2116973; http://dx.doi.org/10.1017/S0950268800047713
   PubMed Web of Science ®Google Scholar
• Tappero J, Lagos R, Maldonado A, Plikaytis B, Williams D, Dykes J, Gheesling LL, Carlone GM, Høiby EA, Holst J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281(16):1520-27; PMID:10227322; http://dx.doi.org/10.1001/jama.281.16.1520
   PubMed Web of Science ®Google Scholar
• Snape M, Pollard A. The beginning of the end for serogroup B meningococcus? Lancet 2013; 381:785-7; PMID:23324564; http://dx.doi.org/10.1016/S0140-6736(12)62194-1
   PubMedGoogle Scholar
• Cofre J. Enfermedad meningocócica: consultas recurrentes. Rev Chil Infectol 2012; 29(6):657-62; PMID:23412036; http://dx.doi.org/10.4067/S0716-10182012000700012
   PubMedGoogle Scholar
• Advisory Committee on Immunization Practices (ACIP). Licensure of meningococcal conjugate vaccine for children aged 2 through 10 years and updated Booster dose guidance for adolescents and other persons at increased risk for meningococcal disease, 2011. MMWR Morb Mortal Wkly Rep 2001; 60:1018-9; PMID:21814165
   PubMedGoogle Scholar
• Ema.europa.eu/Find medicine/Human medicines/European public assessment reports. (Acceded 06.05.2013).
   Google Scholar
• Christensen H, Hickman M, Edmunds WJ, Trotter CL. Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modeling study of potential impact. Vaccine 2013; 31(23):2638-46; PMID:23566946; http://dx.doi.org/10.1016/j.vaccine.2013.03.034
   PubMed Web of Science ®Google Scholar
• Pouwels KB, Hak E, van der Ende A, Christensen H, van den Dobbelsteen GP, Postma MJ. Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence. Hum Vaccin Immunother 2013; 9(5):1-10. Epub ahead of print; PMID:23442580; http://dx.doi.org/10.4161/hv.23888
   PubMedGoogle Scholar
• Constenla D. First Regional Meningococcal Symposium 2012, 19-20 March, Buenos Aires, Argentina. http://www.sabin.org/sites/sabin.org/files/resources/MeningoccalProcSpan_final.pdf
   Google Scholar
• Mohammed I, Onyemelukwe GC, Obineche EN, Gupta N, Oyeyinka GO. Control of epidemic meningococcal meningitis by mass vaccination: II. Persistence of antibody four years after vaccination. J Infect 1984; 9:197-202; PMID:6438245; http://dx.doi.org/10.1016/S0163-4453(84)91468-3
   PubMed Web of Science ®Google Scholar
• Bovier PA, Wyss K, Au HJ. A cost-effectiveness analysis of vaccination strategies against N.meningitidis meningitis in West Africa: a theorical modeling analysis. Vaccine 2001; 14(25-26):3420-31
   Google Scholar
• Galloway Y, Stehr-Green P, McNicholas A, O´Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand Group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38(2):413-8; PMID:18988650; http://dx.doi.org/10.1093/ije/dyn228
   PubMed Web of Science ®Google Scholar
• Campell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 2009; 27S:B20-9; PMID:19477053; http://dx.doi.org/10.1016/j.vaccine.2009.04.067
   PubMedGoogle Scholar
• Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R, Gilca V, Douville-Fradet M, Markowski F, De Wals P. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991–2011: potential implications of emergence of New Strains. PLoS One 2012; 7(11):e50659; PMID:23209803; http://dx.doi.org/10.1371/journal.pone.0050659
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Health surveillance, Brazil. Available at: http://portal.saude.gov.br/portal/saude/area.cfm?id_area=962 (May2008)
   Google Scholar
• Cano R, García C, Mateo S. Enfermedad meningocócica. situación en España en la temporada 1998-1999. Rev Esp Salud Publica [online] 2000; 74(4). ISSN 1135-5727; http://dx.doi.org/10.1590/S1135-57272000000400007
   Google Scholar
• English P. Vaccination against meningitis B: is it worth it? Drugs Context 2013:212246; PMID:24432035; http://dx.doi.org/10.7573/dic.212246
   PubMedGoogle Scholar
• Informe de Resultados de Vigilancia de Laboratorio. Enfermedad Invasora Neisseria meningitidis 2012. Instituto de Salud Pública de Chile. Available at: http://www.ispch.cl/sites/default/files/Informe%20N.m%202012.pdf (accessed 03.06.13)
   Google Scholar
• Davis K, Misurski D, Miller J, Bell T, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the United States. Hum Vaccines 2011; 7(1):96-101; PMID:21278486; http://dx.doi.org/10.4161/hv.7.1.13692
   PubMed Web of Science ®Google Scholar
• Levine OS, Shaffer P, Haddix A, Perkins BA. Cost-effectiveness analysis for routine immunization with a quadrivalent meningococcal polysaccharide (A,C,Y,W135) protein conjugate vaccine in the United States. Presented at the Tenth International Pathogenic Neisseria Conference, Baltimore, MD, September 1996.
   Google Scholar
• Edmond K, Clark A, Korczak V, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10(5):317-28; PMID:20417414; http://dx.doi.org/10.1016/S1473-3099(10)70048-7
   PubMed Web of Science ®Google Scholar
• Donnelly J, Medini D, Giuliani MM, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. 11th European Meningococcal Disease Society EMGM; Ljubljana, Slovenia; May 18–20, 2011:17-18; http://emgm.eu/meetings/emgm2011/abstracts.pdf (Accessed 01.03.2013)
   Google Scholar
• Santolaya ME, O'Ryan M, Valenzuela MT, Prado V, Vergara RF, Muñoz A, Toneatto D, Graña G, Wang H, Dull PM. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013; 9(11):2304-10; PMID:23811804; http://dx.doi.org/10.4161/hv.25505
   PubMed Web of Science ®Google Scholar
• Ramsay M, Andrews N, Trotter C, Kaczmarski E, Miller E. Herd immunity from meningococcal serogroup C conjugated vaccination in England: database analysis. BMJ 2003; 326:365-66; PMID:12586669; http://dx.doi.org/10.1136/bmj.326.7385.365
   PubMed Web of Science ®Google Scholar
• Trotter CL, Edmunds WJ. Modelling cost effectiveness of meningococcal serogroup C conjugated vaccination campaing in England and Wales. BMJ 2002; 324(7341):809; PMID:11934772; http://dx.doi.org/10.1136/bmj.324.7341.809
   PubMed Web of Science ®Google Scholar
• De Wals P, Erickson L. Economic analysis of the 1992-1993 mass immunization campaing against serogrup C meningococcal disease in Quebec. Vaccine 2002; 20(21-22):2840-4; PMID:12102036; http://dx.doi.org/10.1016/S0264-410X(02)00161-5
   PubMedGoogle Scholar
• Maiden MC, Ibarz-Pavon AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, Walker AM, Evans MR, Kroll JS, Neal KR, et al. Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J Infect Dis 2008; 197:737-43; PMID:18271745; http://dx.doi.org/10.1086/527401
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro I, El-Haidi W, Caro JJ. Assesing the economics of vaccination for Neisseria meningitidis in industrialized nations: a review and recommendations for further research. Int J Technol Asses Health Care 2004; 20(3):280-8; PMID:15446757; http://dx.doi.org/10.1017/S0266462304001096
   PubMedGoogle Scholar
• International Monetary Fund, April 2011, http://www.imf.org/external/pubs/ft/weo/2011/01/weodata/index.aspx
   Google Scholar